Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • FALSE CLAIMS ACT—N.D. Ind.: Falsity and Provider’s knowledge of falsity in CPT code use were issues for trial
    • ADMINISTRATION OF FDC ACT—NOTICES: Fee Rate for Using a Priority Review Voucher in Fiscal Year 2025
    • ADVERTISING (FOOD, DRUG & MEDICAL DEVICES)—N.D. Ill.: Alleged unfair practice claim from presence of benzene in Differin acne products survives dismissal
    • CLINICAL RESEARCH—FDA GUIDANCE NOTICES: Conducting Clinical Trials With Decentralized Elements; Guidance for Industry, Investigators, and Other Interested Parties Availability
    • DRUGS AND BIOLOGICS—NOTICES: Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice; Draft Guidance for Industry; Availability
    • ELECTRONIC HEALTH RECORDS—S.D.N.Y.: Privacy violation claim alleging unauthorized disclosure of private health information may proceed
    • EXPERT INSIGHTS—Massachusetts Board Of Pharmacy To Take A Big Step: Licensing Nonresident Pharmacies
    • FRAUD AND ABUSE—E.D.N.Y.: Exclusion of physician from federal health care programs was supported by substantial evidence
    • GENERAL HEALTH CARE NEWS: KFF looks at post-Medicaid ‘unwinding’ enrollment
    • GENERAL HEALTH CARE NEWS—D.S.C.: Products liability claims against maker of Peridox Disinfectant Cleaner may go forward
    • HEALTH CARE EMPLOYMENT ISSUES—N.D. Ill.: Court holds Illinois right of conscience act bars COVID-19 vaccine religious exemption cases
    • LAW FIRM NEWS—Noteworthy developments in the legal community
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, CLINICAL RESEARCH—FDA GUIDANCE NOTICES: Conducting Clinical Trials With Decentralized Elements; Guidance for Industry, Investigators, and Other Interested Parties Availability, (Sep 20, 2024)

    By WK Editorial Staff

    The FDA is announcing the availability of a final guidance for industry, investigators, and other interested parties entitled “Conducting Clinical Trials With Decentralized Elements.”

    This guidance provides recommendations regarding the ...

    By WK Editorial Staff

    The FDA is announcing the availability of a final guidance for industry, investigators, and other interested parties entitled “Conducting Clinical Trials With Decentralized Elements.”

    This guidance provides recommendations regarding the implementation of decentralized elements in clinical trials for drugs, biological products, and devices. Decentralized elements allow trial related activities to occur remotely at locations convenient for trial participants (e.g., telehealth visits with investigators or visits with local healthcare providers (HCPs)). FDA’s regulatory requirements are the same for trials that include decentralized elements and trials that do not include decentralized elements. To help ensure the appropriate oversight trials with decentralized elements, the integrity of trial data, and the safety of trial participants, this guidance covers the responsibilities of sponsors and investigators. This guidance finalizes the draft guidance entitled “Decentralized Clinical Trials for Drugs, Biological Products, and Devices” issued on May 3, 2023. (Notice, 89 Fed. Reg. 76481 (Sept. 18, 2024)).

    Dates. The announcement of the guidance is published in the Federal Register on September 18, 2024.

    FederalRegisterIssuances: FDAGuidanceNotices ClinicalNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use